Global Biotech ImmunoPrecise Makes Strategic Move with New Texas Operations Hub

Rhea-AI Filing Summary

ImmunoPrecise Antibodies filed a Form 6-K (foreign issuer report) on June 28, 2025, indicating the submission of a press release dated June 24, 2025. The filing was signed by Jennifer Bath, who serves as President and Chief Executive Officer.

The company confirms it will file annual reports under Form 20-F rather than Form 40-F. The principal executive office is located in Austin, Texas.

Note: While this is a Form 6-K filing, the actual content and details of the press release (Exhibit 99.1) are not included in this portion of the filing. The Form 6-K serves primarily as a cover document for the attached press release, which would contain the material information being reported to shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 06/24/2025 - 08:00 AM Learn about SEC filing dates

FAQ

What type of SEC filing did IPA submit on June 28, 2025?

ImmunoPrecise Antibodies Ltd. (IPA) submitted a Form 6-K, which is a report of foreign private issuer, filed on June 28, 2025. The filing includes a press release dated June 24, 2025 as Exhibit 99.1.

Who is the current CEO of ImmunoPrecise Antibodies (IPA)?

Jennifer Bath serves as the President and Chief Executive Officer of ImmunoPrecise Antibodies Ltd., as evidenced by her signature on the Form 6-K filing dated June 24, 2025.

Where is IPA's principal executive office located?

ImmunoPrecise Antibodies Ltd.'s principal executive office is located at Industrious 823 Congress Ave Suite 300, Austin, Texas 78701.

Which annual report form does IPA file - Form 20-F or 40-F?

According to the Form 6-K filing, ImmunoPrecise Antibodies Ltd. (IPA) files annual reports under Form 20-F, as indicated by the checked box in the filing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2025.

Commission File Number: 001-39530

ImmunoPrecise Antibodies Ltd.

Industrious 823 Congress Ave Suite 300 Austin, Texas 78701

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release dated June 24, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IMMUNOPRECISE ANTIBODIES LTD.
Date: June 24, 2025
	By:	/s/ Jennifer Bath
	Name:	Jennifer Bath
	Title:	President and Chief Executive Officer